bioAffinity Technologies, Inc. (BIAF)
USD 1.04
(1.96%)
USD 1.04
(1.96%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 791.61 Thousand USD | 12400.53% |
| 2022 | 4336.00 USD | 190.01% |
| 2021 | -4817.00 USD | 78.34% |
| 2020 | -22.24 Thousand USD | 44.78% |
| 2019 | -40.27 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 838.87 Thousand USD | 44.87% |
| 2024 Q1 | 683.31 Thousand USD | 70.95% |
| 2023 Q2 | 18.5 Thousand USD | 2118.71% |
| 2023 FY | 542.02 Thousand USD | 12400.53% |
| 2023 Q4 | 399.71 Thousand USD | 78.62% |
| 2023 Q3 | 223.78 Thousand USD | 1109.36% |
| 2023 Q1 | 834.00 USD | -61.58% |
| 2022 Q2 | 1160.00 USD | 211.65% |
| 2022 Q1 | -1039.00 USD | -30.86% |
| 2022 FY | 4336.00 USD | 190.01% |
| 2022 Q4 | 2171.00 USD | 116.24% |
| 2022 Q3 | 1004.00 USD | -13.45% |
| 2021 Q3 | -1191.00 USD | -0.08% |
| 2021 FY | -4817.00 USD | 78.34% |
| 2021 Q4 | -794.00 USD | 33.33% |
| 2021 Q1 | -1642.00 USD | 0.0% |
| 2021 Q2 | -1190.00 USD | 27.53% |
| 2020 FY | -22.24 Thousand USD | 44.78% |
| 2020 Q4 | - USD | 0.0% |
| 2019 FY | -40.27 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bionano Genomics, Inc. | 9.56 Million USD | 91.725% |
| Prenetics Global Limited | 8.82 Million USD | 91.035% |
| Star Equity Holdings, Inc. | 11.92 Million USD | 93.362% |
| CareDx, Inc | 178.32 Million USD | 99.556% |
| Exact Sciences Corporation | 1.84 Billion USD | 99.957% |
| Exagen Inc. | 29.45 Million USD | 97.313% |
| Inotiv, Inc. | 165.44 Million USD | 99.522% |
| Guardant Health, Inc. | 336.89 Million USD | 99.765% |
| Biodesix, Inc. | 36.07 Million USD | 97.806% |
| BioNexus Gene Lab Corp. | 1.32 Million USD | 40.458% |
| Precipio, Inc. | 6.01 Million USD | 86.846% |
| iSpecimen Inc. | 5.1 Million USD | 84.502% |
| Natera, Inc. | 492.74 Million USD | 99.839% |
| Aspira Women's Health Inc. | 5.26 Million USD | 84.956% |
| Standard BioTools Inc. | 50.45 Million USD | 98.431% |
| 23andMe Holding Co. | 99.37 Million USD | 99.203% |
| Castle Biosciences, Inc. | 174.8 Million USD | 99.547% |
| Personalis, Inc. | 18.2 Million USD | 95.652% |
| Aclaris Therapeutics, Inc. | 13.16 Million USD | 93.988% |
| Applied DNA Sciences, Inc. | 5.53 Million USD | 85.694% |
| OpGen, Inc. | -90.69 Thousand USD | 972.842% |
| T2 Biosystems, Inc. | -8.17 Million USD | 109.689% |
| Myriad Genetics, Inc. | 476.4 Million USD | 99.834% |
| ICON Public Limited Company | 1.81 Billion USD | 99.956% |
| NeoGenomics, Inc. | 244.6 Million USD | 99.676% |
| Star Equity Holdings, Inc. | 11.92 Million USD | 93.362% |
| IDEXX Laboratories, Inc. | 2.18 Billion USD | 99.964% |
| RadNet, Inc. | 93 Million USD | 99.149% |
| MDxHealth SA | 43.92 Million USD | 98.198% |
| Psychemedics Corporation | 8.41 Million USD | 90.591% |
| Illumina, Inc. | 2.74 Billion USD | 99.971% |
| Check-Cap Ltd. | -212 Thousand USD | 473.403% |
| Twist Bioscience Corporation | 133.34 Million USD | 99.406% |
| DarioHealth Corp. | 5.98 Million USD | 86.771% |
| Fulgent Genetics, Inc. | 104.45 Million USD | 99.242% |
| Sera Prognostics, Inc. | 96 Thousand USD | -724.599% |
| ENDRA Life Sciences Inc. | -275.45 Thousand USD | 387.389% |
| OPKO Health, Inc. | 318.12 Million USD | 99.751% |
| Medpace Holdings, Inc. | 524.5 Million USD | 99.849% |
| Neogen Corporation | 463.9 Million USD | 99.829% |
| Intelligent Bio Solutions Inc. | 1.42 Million USD | 44.472% |
| Prenetics Global Limited | 8.82 Million USD | 91.035% |
| Mainz Biomed B.V. | 509.65 Thousand USD | -55.322% |
| Trinity Biotech plc | 19.45 Million USD | 95.93% |
| Neuronetics, Inc. | 51.7 Million USD | 98.469% |
| Sotera Health Company | 577.15 Million USD | 99.863% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | 0.0% |